Glenmark Pharmaceuticals Limited launched Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis. Glenmark is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg.
While the average cost of therapy of top 10 existing brands of the similar drug category is Rs. 365, Glenmark’s Ryaltris-AZ nasal spray has been launched at a breakthrough price of Rs. 175 per pack of 75 metered doses (MD). This cost is around 52% less as compared to the average price of the top 10 brands of the similar drug category.
Ryaltris-AZ nasal spray is a fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. Being a topical therapy Ryaltris-AZ offers many advantages over oral therapies. With technological advantage & competitive pricing with Ryaltris-AZ, Glenmark aims to pass on this benefit to Indian patients who suffer from Moderate to Severe Allergic Rhinitis. Glenmark has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.
